162 related articles for article (PubMed ID: 9380528)
1. [Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms].
Bettin S; Kämpfer I; Seese A; Schäfer A; Reuter M; Lössner J; Dietrich J; Wagner A; Knapp WH
Nuklearmedizin; 1997 Aug; 36(5):167-72. PubMed ID: 9380528
[TBL] [Abstract][Full Text] [Related]
2. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
[TBL] [Abstract][Full Text] [Related]
3. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
Reiche W; Grundmann M; Huber G
Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
[TBL] [Abstract][Full Text] [Related]
4. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease.
Eising EG; Müller TT; Zander C; Kuhn W; Farahati J; Reiners C; Coenen HH
J Investig Med; 1997 Oct; 45(8):448-52. PubMed ID: 9394097
[TBL] [Abstract][Full Text] [Related]
5. Differential alteration of the nigrostriatal dopaminergic system in Wilson's disease investigated with [123I]ss-CIT and high-resolution SPET.
Barthel H; Sorger D; Kühn HJ; Wagner A; Kluge R; Hermann W
Eur J Nucl Med; 2001 Nov; 28(11):1656-63. PubMed ID: 11702107
[TBL] [Abstract][Full Text] [Related]
6. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
Jeon B; Kim JM; Jeong JM; Kim KM; Chang YS; Lee DS; Lee MC
J Neurol Neurosurg Psychiatry; 1998 Jul; 65(1):60-4. PubMed ID: 9667562
[TBL] [Abstract][Full Text] [Related]
7. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
Tatsch K; Schwarz J; Oertel WH; Kirsch CM
Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
[TBL] [Abstract][Full Text] [Related]
8. Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study.
Oliver DW; Dormehl IC; Van der Schyf CJ; Neumeyer JL; Hugo N; Keeve R; Rossouw NT; Müller-Gärtner HW; Castagnoli N
Arzneimittelforschung; 1997 Jun; 47(6):692-9. PubMed ID: 9239444
[TBL] [Abstract][Full Text] [Related]
9. Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study.
Boesch SM; Donnemiller E; Müller J; Seppi K; Weirich-Schwaiger H; Poewe W; Wenning GK
Mov Disord; 2004 Nov; 19(11):1320-5. PubMed ID: 15390003
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H
Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding.
Oder W; Brücke T; Kollegger H; Spatt J; Asenbaum S; Deecke L
J Neural Transm (Vienna); 1996; 103(8-9):1093-103. PubMed ID: 9013397
[TBL] [Abstract][Full Text] [Related]
12. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
[TBL] [Abstract][Full Text] [Related]
13. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters.
Seibyl JP; Laruelle M; van Dyck CH; Wallace E; Baldwin RM; Zoghbi S; Zea-Ponce Y; Neumeyer JL; Charney DS; Hoffer PB; Innis RB
J Nucl Med; 1996 Feb; 37(2):222-8. PubMed ID: 8667048
[TBL] [Abstract][Full Text] [Related]
15. SPET investigations in extrapyramidal diseases using specific ligands.
Staffen W; Hondl N; Trinka E; Zenzmaier R; Ladurner G
Nucl Med Commun; 1997 Feb; 18(2):159-63. PubMed ID: 9076772
[TBL] [Abstract][Full Text] [Related]
16. Striatal dopamine receptors and transporters in monkeys with neonatal temporal limbic damage.
Heinz A; Saunders RC; Kolachana BS; Jones DW; Gorey JG; Bachevalier J; Weinberger DR
Synapse; 1999 May; 32(2):71-9. PubMed ID: 10231127
[TBL] [Abstract][Full Text] [Related]
17. Fentanyl decreases beta-CIT binding to the dopamine transporter.
Bergström KA; Jolkkonen J; Kuikka JT; Akerman KK; Viinamäki H; Airaksinen O; Länsimies E; Tiihonen J
Synapse; 1998 Aug; 29(4):413-5. PubMed ID: 9661259
[TBL] [Abstract][Full Text] [Related]
18. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.
Knudsen GM; Karlsborg M; Thomsen G; Krabbe K; Regeur L; Nygaard T; Videbaek C; Werdelin L
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1631-8. PubMed ID: 15583914
[TBL] [Abstract][Full Text] [Related]
19. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease.
Oertel WH; Tatsch K; Schwarz J; Kraft E; Trenkwalder C; Scherer J; Weinzierl M; Vogl T; Kirsch CM
Ann Neurol; 1992 Dec; 32(6):743-8. PubMed ID: 1471864
[TBL] [Abstract][Full Text] [Related]
20. Iodine-123-IBF SPECT evaluation of extrapyramidal diseases.
Buck A; Westera G; Sutter M; Albani C; Kung HF; vonSchulthess GK
J Nucl Med; 1995 Jul; 36(7):1196-200. PubMed ID: 7790944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
